



Original Research Article

Prescription pattern of non-steroidal anti-inflammatory drugs and their effects on symptoms and disease progression in patients with osteoarthritis in tertiary care centre

Yatish Byndoor^{1*}, Tamilisetti Vidya Sagar², Jayasree Palla³, Divya Agrawal⁴, Sanjay Kumar², Trupti Rekha Swain⁵

¹Dept. of Pharmacology, S Nijalingappa Medical College, Bagalkot, Karnataka, India

²Dept. of Pharmacology, GSL Medical College, Rajahmundry, Andhra Pradesh, India

³Dept. of Community Medicine, GSL Medical College, Rajahmundry, Andhra Pradesh, India

⁴Dept. of Anatomy, GSL Medical College, Rajahmundry, Andhra Pradesh, India

⁵Dept. of Pharmacology, SCB Medical College, Cuttack, Odisha, India



ARTICLE INFO

Article history:

Received 07-05-2022

Accepted 12-12-2022

Available online 13-08-2024

Keywords:

Osteoarthritis

Non-steroidal anti-inflammatory drugs

Cyclooxygenase

ABSTRACT

Objective: Purpose of this study is to evaluate prescribing pattern of NSAIDS in osteoarthritis patients and their effect on symptoms and disease progression

Materials and Methods: The Prospective observational study was performed on 200 study participants of both sexes from orthopaedic Out Patient Department (OPD) from a tertiary care hospital, Prakash Institute of medical science in Kolhapur between span of Aug 2019 to Aug 2020 who were diagnosed with Osteoarthritis and prescribed with NSAIDS for a minimum period of 3 months. After the period of treatment improvement in symptom was assessed by Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) scale to evaluate specific symptoms in subsequent visit at interval of 1 month for 3 follow ups.

Results: Most common NSAIDs prescribed in orthopaedic OPD patients were diclofenac (51%), Paracetamol (50.5%), Aceclofenac (43%), Tramadol (15%), Ibuprofen (7%), etoricoxib (6%), Naproxen (5%). Paracetamol was most frequently prescribed as combination therapy along with diclofenac, Tramadol and aceclofenac, and diclofenac was commonly used as monotherapy. Tramadol combined with paracetamol has been used in only 22 patients (13%) in the present study. Changes in pain, stiffness and physical function subscale after 3 months follow up were significant compare to initial visit in WOMAC score.

Conclusion: Non-steroidal anti-inflammatory drugs are most commonly used drug for the management of pain and inflammation. From our study it was observed that conventional type of NSAIDS are used most common. NSAIDs are vital for clinical management of OA and to improve quality of life. Aceclofenac with paracetamol combination therapy and Diclofenac monotherapy were most frequently prescribed among the NSAIDs. Safety is the proven concern in treating chronic conditions in OA, hence Aceclofenac and Paracetamol is recommended as combination therapy.

This is an Open Access (OA) journal, and articles are distributed under the terms of the [Creative Commons Attribution 4.0 International License](https://creativecommons.org/licenses/by/4.0/), which allows others to remix, and build upon the work. The licensor cannot revoke these freedoms as long as you follow the license terms.

For reprints contact: reprint@ipinnovative.com

1. Introduction

Pain is ‘an unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage’. Furthermore ‘Pain is

* Corresponding author.

E-mail address: dr.yati1988@gmail.com (Y. Byndoor).

always subjective.¹ A wide range of disease conditions involve pain and fever as symptoms. From the very beginning of human civilization, man has been trying to find the way of controlling these symptoms and maintaining good health. As a result, non-steroidal anti-inflammatory drugs (NSAIDs) prescribing as an adjunct to therapy is widely practiced. The lowering of pain thus is an important part of the perception of cure and the overall well-being of the patient.¹ Non-steroidal anti-inflammatory drugs (NSAIDs) are most commonly used drugs for years for management of pain and inflammation with good efficacy and represent most widely prescribed class of medications in the world and are used as over the counter drugs. They work by interfering with cyclooxygenase (COX) pathway, which involves the conversion of arachidonic acid by the enzyme COX to prostaglandins. COX is available in two isoforms i.e., COX-1 and COX-2.²

Management of OA traditionally has focused on treating pain and disability. Clinical guidelines recommend both pharmacologic and nonpharmacologic therapies to relieve symptoms, since no effective remedies to cure OA exist.³ Nonsteroidal anti-inflammatory drugs (NSAIDs) help with symptoms and pain relief^{4–6} but the evidence of long-term effects from oral NSAIDs is still lacking.^{7,8} Moreover, their effect on structural changes in the joint has not been well established. In vitro and animal studies suggest that conventional NSAIDs may have deleterious effects on articular cartilage,^{9,10} whereas cyclooxygenase (COX)-selective NSAIDs might have beneficial or neutral effects.^{11–13} In observational studies of people with knee and hip OA over the age of 55 years, the long-term use of diclofenac appeared to accelerate disease progression.¹⁴

Given the widespread use of NSAIDs and the mounting evidence of their adverse effects,¹⁵ understanding the effectiveness of long-term prescription NSAID use in persons with OA is warranted. In the present study, we sought to estimate the extent to which prescription NSAIDs taken over the long term may not only relieve symptoms, but also delay disease progression

2. Materials and Methods

The Prospective observational study was performed on 200 study participants of both sexes from orthopaedic Out Patient Department (OPD) from a tertiary care hospital, Prakash Institute of medical science in Kolhapur between span of Aug 2019 to Aug 2020 who were diagnosed with Osteoarthritis and prescribed with NSAIDS for a minimum period of 3 months. The data was collected with prior permission from the concern department and the authority. After the period of treatment improvement in symptom was assessed by Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) scale to evaluate specific symptoms in subsequent visit at interval of 1 month for 3 follow-ups.¹⁶ Higher WOMAC scores are suggestive of

worse symptoms; the range of scores was 0–20 for the pain subscale, 0–8 for the stiffness subscale, and 0–68 for the physical function subscale.

Data were entered and analysed using SPSS software version 16.0 version and expressed in descriptive statistics. WOMAC scores (pain, stiffness and physical function) were expressed as mean±standard deviation (SD). WOMAC scores at the first visit and follow-up visit were analysed using student paired t-test. The p-value <0.05 was considered as statistically significant.

2.1. Inclusion criteria

Patients with age between 30-70 years, of either gender, with radiologically confirmed finding of osteoarthritis and those who were fulfilling the clinical or radiological American College of Rheumatology Diagnostic Guidelines for Osteoarthritis Knee (ACR) suffering from joint pain for at least three-month duration with Minimum WOMAC Index score of 40 at the time of screening were included in study.¹⁷

2.2. Exclusion criteria

Patients having other inflammatory joint diseases (rheumatoid arthritis, ankylosing spondylitis, psoriasis, gout, neuropathic, congenital or metabolic conditions affecting joints).

Patients having history of congestive cardiac failure, chronic kidney disease, active peptic ulcer and oesophageal varices.

Pregnant and lactating mothers and patients taking over the counter NSAIDS for pain management were excluded from the study.

3. Results

Among the study population, females were predominant accounting for 63.5% (127) and males were 36.5% (73). Majority of the patients 72% (144) belonged to the age group of 40 to 60 years. More than half of the patients had bilateral OA knee (70.5%) and 72% of patients had pain over the knee joint between 1-3 years of duration.

In our study participants most, common drug prescribed for relieving symptoms and progression of disease in OA patient were NSAIDS. Most common NSAIDS prescribed in orthopaedic OPD patients were diclofenac (51%), Paracetamol (50.5%), Aceclofenac (43%), Tramadol (15%), Ibuprofen (7%), etoricoxib (6%), Naproxen (5%). Paracetamol was most frequently prescribed as combination therapy along with diclofenac, Tramadol and aceclofenac, and diclofenac was commonly used as monotherapy. Tramadol combined with paracetamol has been used in only 22 patients (13%) in the present study. Changes in pain, stiffness and physical function subscale after 3 months follow up were significant compare to initial visit

in WOMAC score.

Table 1: Demographic and clinical features of study participants

Demographic data	Number of patient (n=200)
Age	
<40 Y	14
40-60	144
60-70	42
Gender	
Male	73
Female	127
Duration of disease	
<1 year	22
1-3 year	146
>3 year	32
Site of Osteoarthritis	
Knee involvement	141
Other joints	59




Figure 1: Bar diagram showing prescribing pattern of NSAIDS




Figure 2: Pie diagram showing combination of NSAIDs in prescriptions

Table 2: Prescription pattern in OA patients

Name of drug	Number of prescriptions Monotherapy	Combination therapy	Total	Percentage (%)
Paracetamol	09	92	101	50.5
Diclofenac	22	80	102	51
Aceclofenac	18	68	86	43
Naproxen	02	8	10	5
Ibuprofen	02	12	14	7
Etoricoxib	08	04	12	6
Tramadol	6	24	30	15

Table 3: Common NSAIDS combination

Drugs	Total
Diclofenac + Paracetamol	74
Aceclofenac + Paracetamol	58
Tramadol + Paracetamol	22

Table 4: WOMAC score for pain, stiffness, physical function during first and follow-up visits.

WOMAC subscale score Mean $\pm$ SD	1 st Visit	2 nd Follow up visit	3 rd Follow up visit	P value
Pain	3.4 $\pm$ 3.7	4.8 $\pm$ 3.7	4.9 $\pm$ 4	<0.05
Stiffness	1.9 $\pm$ 1.7	2.4 $\pm$ 1.8	2.4 $\pm$ 1.8	<0.05
Physical function	10.4 $\pm$ 11.6	14.6 $\pm$ 13.1	15.5 $\pm$ 12.8	<0.05

4. Discussion

Among the study population, females were predominant, as supported by Gupta R et al., and Poornima B et al.^{18,19} This female patient was the major risk factor for OA due to their lack of physical activity, mobility. Majority of the study participants suffering from OA were in the middle age group between 40-60 which is similar to the study conducted by Gurung S et al.²⁰ The present study results were comparable with the study conducted by Poornima B et al., and Venkatachalam J et al., where knee joint was commonly involved in OA.^{19,21}

Pharmacological treatment is aimed to relieve the signs and symptoms and indeed, to reduce disease progression with improvement in QoL. Based on this, most frequently prescribed drug class was NSAIDs similar to study done by Sahayam JSA et al., where NSAIDs were commonly prescribed.²²

Poornima B et al. study showed Etoricoxib and aceclofenac were the frequently prescribed drug as monotherapy and among the combination therapy, Paracetamol was most prescribed with Aceclofenac, Diclofenac and Tramadol as compared with present study observation.¹⁸

The improvement in quality of life using WOMAC score were comparable with similar studies like lapane et al.²³

5. Conclusion

Non-steroidal anti-inflammatory drugs are most commonly used drug for the management of pain and inflammation. From our study it was observed that conventional type of NSAIDs are used in our institute. NSAIDs are vital for clinical management of OA and to improve quality of life. Aceclofenac with paracetamol combination therapy and Diclofenac monotherapy were most frequently prescribed among the NSAIDs. Safety is the proven concern in treating chronic conditions in OA, hence Aceclofenac and Paracetamol is recommended as combination therapy. This study indicates that oral NSAIDs when promptly used could provide promising relief of pain, improve physical function and Quality of Life (QoL). In conclusion, long-term use

of NSAIDs was associated with improvement in patients' reports of stiffness and function as well as quality of life of patients.

6. Conflict of Interest

None.

7. Source of Funding

None.

References

1. Rahman M, Begum Z, Samad M. Prescribing Pattern of Non-Steroidal Anti-Inflammatory Drugs at Outpatient Departments of Teaching Hospitals. *Bangladesh J Pharmacol.* 2008;2(1):9–13.
2. Vane J. Inhibition of Prostaglandin Synthesis as a Mechanism of Action for Aspirin-like Drugs. *Nat New Biol.* 1971;231(25):232–5.
3. Hochberg MC, Altman RD, April KT, Benkhalti M, Guyatt G, McGowan J, et al. American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. *Arthritis Care Res (Hoboken).* 2012;64(4):465–74.
4. Bjordal JM, Ljunggren AE, Klovning A, Slordal L. Non-steroidal anti-inflammatory drugs, including cyclo-oxygenase-2 inhibitors, in osteoarthritic knee pain: meta-analysis of randomised placebo controlled trials. *BMJ.* 2004;329(7478):1317. doi:10.1136/bmj.38273.626655.63.
5. Deeks JJ, Smith LA, Bradley MD. Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials. *BMJ.* 2002;325(7365):619. doi:10.1136/bmj.325.7365.619.
6. Adatia A, Rainsford KD, Kean WF. Osteoarthritis of the knee and hip. Part II: therapy with ibuprofen and a review of clinical trials. *J Pharm Pharmacol.* 2012;64(5):626–36.
7. Bjordal JM, Klovning A, Ljunggren AE, Slordal L. Short-term efficacy of pharmacotherapeutic interventions in osteoarthritic knee pain: a meta-analysis of randomised placebo-controlled trials. *Eur J Pain.* 2007;11(2):125–38.
8. Pavelka K. A comparison of the therapeutic efficacy of diclofenac in osteoarthritis: a systematic review of randomised controlled trials. *Curr Med Res Opin.* 2012;28(1):163–78.
9. Ding C. Do NSAIDs affect the progression of osteoarthritis? *Inflammation.* 2002;26(3):139–42.
10. Gencosmanoglu BE, Eryavuz M, Dervisoglu S. Effects of some nonsteroidal anti-inflammatory drugs on articular cartilage of rats in an experimental model of osteoarthritis. *Res Exp Med (Berl).* 2001;200(3):215–26.

11. Mastbergen SC, Jansen NW, Bijlsma JW, Lafeber FP. Differential direct effects of cyclo-oxygenase-1/2 inhibition on proteoglycan turnover of human osteoarthritic cartilage: an in vitro study. *Arthritis Res Ther*. 2006;8:2–2. doi:10.1186/ar1846.
12. Mastbergen SC, Marijnissen AC, Vianen ME, Zoer B, Van Roermund P, Bijlsma JW, et al. Inhibition of COX-2 by celecoxib in the canine groove model of osteoarthritis. *Rheumatology (Oxford)*. 2006;45(4):405–13.
13. Hajjaji HE, Marcelis A, Devogelaer JP, Manicourt DH. Celecoxib has a positive effect on the overall metabolism of hyaluronan and proteoglycans in human osteoarthritic cartilage. *J Rheumatol*. 2003;30(11):2444–51.
14. Reijman M, Bierma-Zeinstra SM, Pols HA, Koes BW, Stricker BH, Hazes JM, et al. Is there an association between the use of different types of nonsteroidal antiinflammatory drugs and radiologic progression of osteoarthritis? The Rotterdam Study. *Arthritis Rheum*. 2005;52(10):3137–42.
15. Fendrick AM, Greenberg BP. A review of the benefits and risks of nonsteroidal anti-inflammatory drugs in the management of mild to-moderate osteoarthritis. *Osteopath Med Prim Care*. 2009;3:1. doi:10.1186/1750-4732-3-1.
16. Roos EM, Klassbo M, Lohmander LS. WOMAC osteoarthritis index. Reliability, validity, and responsiveness in patients with arthroscopically assessed osteoarthritis. *Scand J Rheumatol*. 1999;28(4):210–5.
17. Kawasaki T, Inoue K, Ushiyama T, Fukuda S. Assessment of the American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the knee. *Ryumachi*. 1998;38(1):2–5.
18. Gupta R, Malhotra A, Malhotra P. Study of prescription pattern of drugs used in the treatment of osteoarthritis in a tertiary care teaching hospital- An observational study. *Int J Res Sci*. 2018;6(3):985–9.
19. Poornima B, Bhandare B, Kalamadani AR, Yashaswini B. Prescription pattern of drugs in osteoarthritis. *IJPRS*. 2015;4(3):27–33.
20. Gurung S, Babu S, Sabu S, Shibu RM, Begum R, Nanjwade BK, et al. A study on prescribing pattern in the management of osteoarthritis and rheumatoid arthritis in the department of orthopaedics. *WJPPS*. 2016;5(4):1472–93.
21. Venkatachalam J, Natesan M, Eswaran M, Johnson AK, Bharath V, Singh Z, et al. Prevalence of osteoarthritis of knee joint among adult population in a rural area of Kanchipuram District, Tamil Nadu. *Indian J Public Health*. 2018;62(2):117–22.
22. Sahayam JSA, Kulandaiammal M, Prakash M. Pattern of drug prescribing in osteoarthritis patients attending orthopaedic outpatient department of a tertiary care hospital. *J Drug Del Ther*. 2016;6(5):14–7.
23. Lapane KL, Yang S, Driban JB, Liu SH, Dubé CE, Dubé CE, et al. Effects of prescription non-steroidal anti-inflammatory agents on symptoms and disease progression among patients with knee osteoarthritis. *Arthritis Rheumatol*. 2015;67(3):724–32.

Author biography

Yatish Byndoor, Assistant Professor

Tamilisetti Vidya Sagar, Professor

Jayasree Palla, Associate Professor

Divya Agrawal, Professor

Sanjay Kumar, Professor

Trupti Rekha Swain, Professor

Cite this article: Byndoor Y, Sagar TV, Palla J, Agrawal D, Kumar S, Swain TR. Prescription pattern of non-steroidal anti-inflammatory drugs and their effects on symptoms and disease progression in patients with osteoarthritis in tertiary care centre. *Panacea J Med Sci* 2024;14(2):332-336.